Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study

Published:2024-03-22 Issue:5 Volume:27 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Liu Qing¹,Fu Ying²,Guo Jun²,Fu Chunqiu³,Tang Ning²,Zhang Chufeng²,Han Xiao²,Wang Zhehai²

Affiliation:

1. Department of Medical Oncology, Shandong Cancer Hospital and Institute, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250117, P.R. China

2. Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China

3. Department of Oncology, Changqing People's Hospital, Jinan, Shandong 250300, P.R. China

Publisher

Spandidos Publications

Reference39 articles.

1. Systemic treatment of brain metastases in non-small cell lung cancer;Page;Eur J Cancer,2020

2. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases;Costa;J Clin Oncol,2015

3. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK;Shaw;J Clin Oncol,2009

4. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced non-small cell lung cancer;Lee;Cancer,2012

5. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma;Kang;Respir Med,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP